奥利万星对万古霉素敏感和耐药肠球菌浮游菌态及生物被膜态的体外活性。

In vitro activity of oritavancin against planktonic and biofilm states of vancomycin-susceptible and vancomycin-resistant enterococci.

作者信息

Yan Qun, Karau Melissa J, Patel Robin

机构信息

Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; Department of Clinical Laboratory, Xiangya Hospital of Central South University, Changsha, Hunan, China.

Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

出版信息

Diagn Microbiol Infect Dis. 2018 Aug;91(4):348-350. doi: 10.1016/j.diagmicrobio.2018.03.008. Epub 2018 Mar 16.

DOI:10.1016/j.diagmicrobio.2018.03.008

PMID:29678300

Abstract

We tested the in vitro activity of oritavancin against 60 vancomycin-susceptible enterococci (VSE) and 27 vancomycin-resistant enterococci (VRE). The oritavancin MIC ranged from ≤0.002 to 0.5μg/mL; the minimum biofilm bactericidal concentration ranged from ≤0.002 to 2μg/mL. Oritavancin has promising in vitro activity against VSE and VRE in both planktonic and biofilm states.

摘要

我们测试了奥利万星对60株万古霉素敏感肠球菌（VSE）和27株万古霉素耐药肠球菌（VRE）的体外活性。奥利万星的最低抑菌浓度范围为≤0.002至0.5μg/mL；最低生物膜杀菌浓度范围为≤0.002至2μg/mL。奥利万星在浮游和生物膜状态下对VSE和VRE均具有良好的体外活性。